Home » Impax Refiles NDA After Manufacturing Woes
Impax Refiles NDA After Manufacturing Woes
Impax said Friday it has refiled an NDA for its Parkinson’s disease drug Rytary after implementing quality systems improvements at the plant where the drug was slated to be made.
Drug Industry Daily
Drugs Regulatory Affairs Submissions and ApprovalsDrug Industry Daily
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May